Tyrphostin AG213

Cat. No.:	HY-101959
CAS No.:	122520-86-9
Molecular Formula:	$C_{10}H_8N_2O_2S$
Molecular Weight:	220.25
Target:	EGFR; Topoisomerase
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Tyrphostin AG213 (AG213) is an inhibitor of epidermal growth factor receptor (EGFR) protein tyrosine kinase (IC_{50}=0.85 μM). Tyrphostin AG213 inhibits tyrosine kinase activity IC_{50}=2.4 μM) and topoisomerase II (IC_{100}=50 μM). Tyrphostin AG213 can induce nonapoptotic cell programmed death in tumor cells[1][2][3].
In Vitro	Tyrphostin AG213 (25 μM, 50 μM, and 75 μM; 24 h, 48 h, and 96 h) increases wound closure time in human umbilical vein endothelial cell (HUVEC) monolayer[1]. Tyrphostin AG213 (100 μM; 1 h) interferes with HUVEC focal adhesion and stress fiber formation[1]. Tyrphostin AG213 (100 μM; 24 h) inhibits adherence-related tyrosine phosphorylation of pp125FAK in HUVEC[1]. Tyrphostin AG213 (10 μM; 24 h) inhibits tyrosine kinase activity, and (4.55-455 mM; 24-72 h) inhibits HT-29 cell viability dose- and time-dependently[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Romer LH, et al. Tyrosine kinase activity, cytoskeletal organization, and motility in human vascular endothelial cells. Mol Biol Cell. 1994 Mar;5(3):349-61.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA